Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Valeant Pharmaceuticals
Valeant Pharmaceuticals
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Sobi enters into new distribution agreement with Valeant for Ammonul
The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
You need to be a subscriber to read this article.
Click here
to find out more.
Media
A precision medicine approach to developing cancer vaccines
Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Design & Build
Valeant Canada expands with $27.5m investment
The company will expand manufacturing and exporting capacity in Steinbach, Manitoba and Laval, Quebec
Valeant Pharmaceuticals names Joseph Papa as Chairman and Chief Executive
He brings more than 30 years of leadership and operations experience in healthcare to the firm
Valeant Pharmaceuticals makes management change
In its US Dermatology and Gastrointestinal businesses
J. Michael Pearson returns as CEO of Valeant following illness
Robert A. Ingram appointed Chairman of the Board as the roles of Chairman and CEO are separated
Regulatory
Opinion: Politics, passion and patient power
Did political correctness play a greater role than therapeutic efficacy in the FDA's decision to approve the 'pink Viagra'?
Subscribe now